Is the high cost of psychedelic therapy worth it?

This helpful article in Lucid News comment: "Psychedelic treatments are right around the corner. If everything goes right, MDMA-assisted therapy for PTSD will be FDA approved by the end of 2024. Similarly, psilocybin for treatment-resistant depression might see approval by 2026.  Who will pay for these treatments? Unlike an antidepressant, psychedelics will not be a take-home treatment. Compared to traditional talk therapy, the hours invested upfront will be much higher. Will insurance companies pay for psychedelic-assisted therapies?  In this column I will examine the costs and benefits of psychedelic-assisted therapy, look at ketamine for depression as a comparator, and show that the economic case for PAT to be less certain than many believe."

For more psychedelic news and research, visit the psychedelic health professional network homepage.

Previous
Previous

Psychedelics for patients with cancer: A comprehensive literature review

Next
Next

Could ketamine-assisted therapy help treat alcohol disorder?